Berberine as a Multi‐Targeted Therapeutic Agent in Melanoma: Mechanisms, Efficacy, and Combination Therapies
Drug Development Research · 2025
DOI: 10.1002/ddr.70144 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Drug Development Research, 2025. Verfasst von Rong-Rong Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Disease Center, the First Affiliated Hospital of Nanchang University, the First Clinical Medical College of Nanchang University,…. Hauptthemen laut MEDLINE: Berberine, Melanoma, Antineoplastic Agents. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 84 Literaturangaben. Gefördert von: This study was supported in part by the Natural Science Foundation of Jiangxi Province Youth Project (20242BAB20404), Jiangxi Province 'Ganpo Talent Program' i….
Abstract (Originalsprache)
Melanoma is a type of aggressive cancer distinguished by its high propensity for recurrence, the development of metastases, and an unfavorable outlook for recovery. Treatment modalities for melanoma encompass surgery, immunotherapy, and targeted therapies. In recent decades, berberine has garnered attention for its significant anticancer properties across various cancer types. This review systematically examines the molecular mechanisms of berberine in melanoma, particularly its modulation of critical signaling pathways, including B‐RAF/MEK/ERK, PI3K/AKT, and NF‐κB, which are essential for regulating melanoma cell proliferation and promoting apoptosis. Furthermore, berberine activates AMP‐activated protein kinase, leading to the inhibition of cyclooxygenase‐2, thereby reducing melanoma cell migration and invasion through decreased inflammation and enhanced cellular energy regulation. It also induces mitochondrial dysfunction and oxidative stress, promoting apoptosis while simultaneously inhibiting epithelial‐to‐mesenchymal transition, a key process in metastasis. Additionally, berberine modulates the immune microenvironment through Toll‐like receptors, cytokine networks, and the regulation of various immune cells, thereby enhancing its antitumor effects. Recent studies have shown that the therapeutic effect of berberine is enhanced when used in combination with other therapies, especially immune checkpoint inhibitors, to improve antitumor immune responses. These findings highlight the potential of berberine as a multi‐targeted agent for the treatment of melanoma, providing an avenue for further clinical exploration and integration into therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Disease Center, the First Affiliated Hospital of Nanchang University, the First Clinical Medical College of Nanchang University, Jiangxi Medical College, Nanchang, P.R. China.
- Department of Hepatobiliary and Pancreatic Surgery, the Eighth Affiliated Hospital, Sun Yat-sen University, Shenzhen, P.R. China.
ORCID-Profile: Rong-Rong Wang
Förderung
- This study was supported in part by the Natural Science Foundation of Jiangxi Province Youth Project (20242BAB20404), Jiangxi Province 'Ganpo Talent Program' i…
Zitieren
APA
Wang, R. R., Wu, H., Feng, M. L., Zhong, J. L., Li, R. X., & Zhou, B. X. (2025). Berberine as a Multi‐Targeted Therapeutic Agent in Melanoma: Mechanisms, Efficacy, and Combination Therapies. Drug Development Research. https://doi.org/10.1002/ddr.70144
Vancouver
Wang RR, Wu H, Feng ML, Zhong JL, Li RX, Zhou BX. Berberine as a Multi‐Targeted Therapeutic Agent in Melanoma: Mechanisms, Efficacy, and Combination Therapies. Drug Development Research. 2025. doi:10.1002/ddr.70144
BibTeX
@article{Wang2025,
author = {Wang, Rong-Rong and Wu, Hui and Feng, Meng-Ling and Zhong, Jia-Li and Li, Rui-Xi and Zhou, Bo-Xuan},
title = {Berberine as a Multi‐Targeted Therapeutic Agent in Melanoma: Mechanisms, Efficacy, and Combination Therapies},
journal = {Drug Development Research},
year = {2025},
doi = {10.1002/ddr.70144}
}
EUVIMED